Frank P Hull MD

Internal Medicine•Plantation, FL

Critical Care Medicine, Sleep Medicine, Pulmonology

Pulmonologist & Sleep Medicine Specialist at Broward Pulmonary and Sleep Specialists

Join to View Full Profile

10059 NW 1st CtPlantation, FL 33324
Phone+1 954-522-7226
Fax+1 954-388-2222

Summary

Dr. Frank Hull is an Internal Medicine specialist located in Plantation, FL, with subspecialties in Critical Care Medicine, Sleep Medicine, and Pulmonology. He completed his residency in Internal Medicine at Albert Einstein East Campus, Bronx NY and a fellowship in Pulmonary Disease and Critical Care Medicine at NYU Grossman School of Medicine. Dr. Hull has been a pulmonologist at Westside Regional Medical Center since 2021 and has served as a Professor at Nova Southeastern University since 2004. Dr. Hull also has priviliges at Broward Health, Memorial West, Holy Cross and Kindred Hospital in Fort Lauderdale. Dr. Hull has been at Broward Pulmonary & Sleep Specialists since 2003 and is now the managing partner. Dr. Hull interests include Bronchoscopy and Interventional Pulmonology, Asthma, Chronic obstructive pulmonary disease. Dr. Hull has published several research articles, particularly on venous thromboembolism. Dr. Hull's currently has a large clinical trial unit focusing on respiratory diseases with over 10 trials completed and 5 more enrolling.

Education & Training

NYU Grossman School of MedicineFellowship, Pulmonary Disease and Critical Care Medicine, 1997 - 2001
Jacobi Medical Center/Albert Einstein College of MedicineResidency, Internal Medicine, 1994 - 1997
University of Pretoria Faculty of MedicineClass of 1990

Certifications & Licensure

FL State Medical License 2003 - 2027
NY State Medical License 2001 - 2005
American Board of Internal Medicine Critical Care Medicine
American Board of Internal Medicine Pulmonary Disease
American Board of Internal Medicine Sleep Medicine

Awards, Honors, & Recognition

President's Award Nova Southeastern Univerisity, 2010
Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program Start of enrollment: 2011 Jun 01
Completed
Retrospective Chart Review of First-time Opsumit® (Macitentan) Users in the United States Start of enrollment: 2017 Aug 03
COMPLETED
Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19. Start of enrollment: 2020 Jun 12
Completed
Phase 2
Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease Start of enrollment: 2020 May 28
COMPLETED
PHASE2
Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level Start of enrollment: 2019 Oct 30
COMPLETED
PHASE3
A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis Start of enrollment: 2020 Dec 01
COMPLETED
PHASE3
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations Start of enrollment: 2022 Jan 03
ACTIVE_NOT_RECRUITING
PHASE3
A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype Start of enrollment: 2021 Jan 26
ACTIVE_NOT_RECRUITING
PHASE3
BURAN: Benralizumab on Airway Dynamics in Severe Eosinophilic Asthma Using Functional Respiratory Imaging Start of enrollment: 2022 Oct 11
COMPLETED
PHASE4
Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) Start of enrollment: 2021 Feb 12
ACTIVE_NOT_RECRUITING
PHASE3
A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis Start of enrollment: 2024 Feb 20
ACTIVE_NOT_RECRUITING
PHASE2
BLU-5937: First-in-Human, Single and Multiple Doses Escalation, Safety, Tolerability, Pharmacokinetics and Food Effect Start of enrollment: 2018 Jul 09
Completed
Phase 1
OPsumit USers Registry Start of enrollment: 2014 Apr 30
COMPLETED
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma Start of enrollment: 2024 Nov 07
RECRUITING
PHASE2
Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO). Start of enrollment: 2023 Mar 06
RECRUITING
PHASE3
Join now to see all

Publications & Presentations

PubMed

1 citations
Best practices for implementing venous thromboembolism prophylaxis across the continuum of care.
Paul P. Dobesh, Tania Ahuja, George A. Davis, Hugh Fatodu, William H. Francis
The American Journal of Managed Care. 2018-11-01
Diagnosing pulmonary emboli: a critical review for the clinician and radiologist.
Yair Safriel, Frank Hull
The Yale Journal of Biology and Medicine. 2005-05-01
35 citations
Regional Deposition of Aerosolized Interferon-γ in Pulmonary Tuberculosis
Rany Condos, Frank P. Hull, Neil W. Schluger, William N. Rom, Gerald C. Smaldone
Chest. 2004-06-01

Journal Articles

Predicting Lung Deposition with a Cascade Impactor
Sangwan S, Hull F, CondosR, Smaldone GC, Journal of Aerosol Medicine, 2001
High Levels of Plasma IL-10 does not diminish purified protein derivative (PPD) skin induration size
FP Hull, R Condos, WN Rom, AJRCCM, 3/1999

Abstracts/Posters

Assessing Fatigue in Commercial Airline Pilots Using The Trail Making Test
Llewellyn Boyer-Cartwright, Stephanie Silberman Ph.D. , Frank Hull M.D., American Academy of Sleep Medicine, Denver, CO, 6/1/2005
Deposition of aerosolized interferon gamma in patients with tuberculosis & A novel method for measuring upper airway aerosol deeposition
F.P. Hull, R. Condos, W.N. Rom, G.C. Smaldone, American Thoracic Society (ATS) International Conference, San Francisco, CA, 2001
Clinical Efficacy Of Long Term Treatment With Pyrazinamide (PZA) In Multi Drug Resistant Tuberculosis (MDR-TB)
F.P. Hull, American Thoracic Society (ATS) International Conference, Toronto, Canada, 2000
High Levels of Plasma IL-10 does not diminish purified protein derivative (PPD) skin induration size
FP Hull, R Condos, WN Rom, American Thoracic Society International Conference, San Diego, CA, 5/1/1999
Join now to see all

Committees

Chair, Pharmacy and Therapeutic Committee, Kindred Fort Lauderdale 2008 - Present
Member, Cancer Committee, Broward Health Medical Center 2004 - Present
Chief of Staff, Medical Executive Committee, Kindred Fort Lauderdale 2011 - 2012